Lenacapavir: could new HIV drug help end the pandemic?
\u201cThat will be a miracle on its own because when I started taking ARVs I began with 20 tablets.\u201d
In June, the US drug company Gilead announced that a trial of its HIV drug Lenacapavir had got a 100% success rate.
The drug - a twice-yearly injection \u2013 can be used to protect people from catching the virus, but also to treat those who have it.
But the question of pricing remains \u2013 with people in poor countries unable to afford the current price tag of $40,000 per person per year. One analysis has suggested it could be mass produced as a generic drug for about $40 per person per year.
In this episode of Africa Daily podcast Peter Musembi speaks to Dr Moupali Das who oversees the development of HIV prevention drugs at Gilead \u2013 and also gets reaction with two people living with HIV.